The Histone Modification Code in the Pathogenesis of Autoimmune Diseases
Autoimmune diseases are chronic inflammatory disorders caused by a loss of self-tolerance, which is characterized by the appearance of autoantibodies and/or autoreactive lymphocytes and the impaired suppressive function of regulatory T cells. The pathogenesis of autoimmune diseases is extremely comp...
Saved in:
Main Authors: | , |
---|---|
Format: | Book |
Published: |
Hindawi Limited,
2017-01-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
MARC
LEADER | 00000 am a22000003u 4500 | ||
---|---|---|---|
001 | doaj_b2b9c49d1d134d1f95c8a55959d882f2 | ||
042 | |a dc | ||
100 | 1 | 0 | |a Yasuto Araki |e author |
700 | 1 | 0 | |a Toshihide Mimura |e author |
245 | 0 | 0 | |a The Histone Modification Code in the Pathogenesis of Autoimmune Diseases |
260 | |b Hindawi Limited, |c 2017-01-01T00:00:00Z. | ||
500 | |a 0962-9351 | ||
500 | |a 1466-1861 | ||
500 | |a 10.1155/2017/2608605 | ||
520 | |a Autoimmune diseases are chronic inflammatory disorders caused by a loss of self-tolerance, which is characterized by the appearance of autoantibodies and/or autoreactive lymphocytes and the impaired suppressive function of regulatory T cells. The pathogenesis of autoimmune diseases is extremely complex and remains largely unknown. Recent advances indicate that environmental factors trigger autoimmune diseases in genetically predisposed individuals. In addition, accumulating results have indicated a potential role of epigenetic mechanisms, such as histone modifications, in the development of autoimmune diseases. Histone modifications regulate the chromatin states and gene transcription without any change in the DNA sequence, possibly resulting in phenotype alteration in several different cell types. In this paper, we discuss the significant roles of histone modifications involved in the pathogenesis of autoimmune diseases, including rheumatoid arthritis, systemic lupus erythematosus, systemic sclerosis, primary biliary cirrhosis, and type 1 diabetes. | ||
546 | |a EN | ||
690 | |a Pathology | ||
690 | |a RB1-214 | ||
655 | 7 | |a article |2 local | |
786 | 0 | |n Mediators of Inflammation, Vol 2017 (2017) | |
787 | 0 | |n http://dx.doi.org/10.1155/2017/2608605 | |
787 | 0 | |n https://doaj.org/toc/0962-9351 | |
787 | 0 | |n https://doaj.org/toc/1466-1861 | |
856 | 4 | 1 | |u https://doaj.org/article/b2b9c49d1d134d1f95c8a55959d882f2 |z Connect to this object online. |